Core Insights - VolitionRx Limited has successfully demonstrated the ability to quantify nucleosomes in whole venous blood using a simple lateral flow device, which can provide rapid results in minutes [1] - The study involved 25 hospital patients and showed strong correlation with Volition's established Nu.Q® nucleosome assay, indicating potential for early detection of immune disruptions in conditions like sepsis [1][3] - The technology represents a significant advancement as it allows for quantitative results rather than just positive/negative outcomes, facilitating better clinical decision-making [3] Company Overview - VolitionRx is a multi-national epigenetics company focused on developing blood tests for early disease detection and monitoring, particularly in conditions associated with NETosis, such as sepsis [6][7] - The company aims to improve patient outcomes through earlier detection and monitoring, which can prolong life and enhance quality of life [7] - Volition's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8] Technological Innovation - The SUMMIT program is focused on developing a capillary blood-based lateral flow test for early sepsis diagnosis, supported by the Walloon Region [3] - The lateral flow test technology is designed for ease of use, allowing for immediate testing in various settings without the need for specialized equipment [4] - The Nu.Q® nucleosome assay is a chemiluminescent immunoassay that is already available in 27 European countries and is CE marked for disease detection [5] Market Potential - The rapid identification of high-risk patients at the point-of-care could lead to quicker clinical decisions and improved patient outcomes, particularly in critical conditions like sepsis [2] - The technology has the potential to be particularly beneficial in lower-income countries where laboratory infrastructure may be lacking [2]